Prognostic and predictive value of the Arbeitsgemeinschaft Gynaekologische Onkologie (AGO) score in surgery for recurrent ovarian cancer

Gynecologic Oncology

Volumn 132, Issue 3, 2014, Pages 537-541

  Harter, Philipp ^a,b   Beutel, Bianca ^a,b   Alesina, Piero F ^a   Lorenz, Dietmar ^b   Boergers, Andre ^a   Heitz, Florian ^a,b   Hils, Rita ^b   Kurzeder, Christian ^a   Traut, Alexander ^a,b   Du Bois, Andreas ^a,b  

^a KLINIKEN ESSEN MITTE   (Germany)

^b DR HORST SCHMIDT KLINIKEN   (Germany)

Author keywords

AGO score; Cytoreductive surgery; Ovarian cancer; Relapse

Indexed keywords

ABDOMINAL INFECTION; ADOLESCENT; ADULT; AGED; ANASTOMOSIS LEAKAGE; ARBEITSGEMEINSCHAFT GYNAEKOLOGISCHE ONKOLOGIE SCORE; ARTICLE; BLADDER FISTULA; CANCER PATIENT; CANCER PROGNOSIS; CANCER RECURRENCE; CANCER SURVIVAL; CYTOREDUCTIVE SURGERY; ENTEROPATHY; EXPLORATORY RESEARCH; FEMALE; FOLLOW UP; HUMAN; MAJOR CLINICAL STUDY; MIDDLE AGED; OUTCOME ASSESSMENT; OVARY CANCER; OVERALL SURVIVAL; PANCREAS FISTULA; POSTOPERATIVE COMPLICATION; POSTOPERATIVE HEMORRHAGE; PREDICTIVE VALUE; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; RETROSPECTIVE STUDY; SCORING SYSTEM; SEPSIS; SURGICAL WOUND; VERY ELDERLY; YOUNG ADULT;

AGO SCORE; CYTOREDUCTIVE SURGERY; OVARIAN CANCER; RELAPSE;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; FEMALE; HUMANS; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; OVARIAN NEOPLASMS; PREDICTIVE VALUE OF TESTS; PROGNOSIS; SEVERITY OF ILLNESS INDEX; YOUNG ADULT;

EID: 84896395212     PISSN: 00908258     EISSN: 10956859     Source Type: Journal    
DOI: 10.1016/j.ygyno.2014.01.027     Document Type: Article

References (16)

1. P. Harter, M.Z. Muallem, C. Buhrmann, D. Lorenz, C. Kaub, and R. Hils et al. Impact of a structured quality management program on surgical outcome in primary advanced ovarian cancer Gynecol Oncol 121 2011 615 619
2. R.A. Burger, M.F. Brady, M.A. Bookmann, G.F. Fleming, B.J. Monk, and H. Huang et al. Incorporation of bevacizumab in the primary treatment of ovarian cancer N Engl J Med 365 26 2011 2473 2483
3. T.J. Perren, A.M. Swart, J. Pfisterer, J.A. Ledermann, E. Pujade-Lauraine, and G. Kristensen et al. A phase 3 trial of bevacizumab in ovarian cancer N Engl J Med 365 26 2011 2484 2496
4. A. du Bois, A. Reuss, E. Pujade-Lauraine, P. Harter, I. Ray-Coquard, and J. Pfisterer Role of surgical outcome as prognostic factor in advanced epithelial ovarian cancer: a combined exploratory analysis of 3 prospectively randomized phase 3 multicenter trials: by the Arbeitsgemeinschaft Gynaekologische Onkologie Studiengruppe Ovarialkarzinom (AGO-OVAR) and the Groupe d'Investigateurs Nationaux Pour les Etudes des Cancers de l'Ovaire (GINECO) Cancer 115 6 Mar 15 2009 1234 1244
5. P. Harter, F. Hilpert, S. Mahner, F. Heitz, J. Pfisterer, and A. du Bois Systemic therapy in recurrent ovarian cancer: current treatment options in new drugs Expert Rev Anticancer Ther 10 2010 81 88
6. A. Poveda, I. Vergote, S. Tjulandin, B. Kong, M. Roy, and S. Chan et al. Trabectedin plus pegylated liposomal doxorubicin in relapsed ovarian cancer: outcomes in the partially platinum-sensitive (platinum-free interval 6-12 months) subpopulation of OVA-301 phase III randomized trial Ann Oncol 22 2011 39 48
7. C. Aghajanian, S.V. Blank, B.A. Goff, P.L. Judson, M.G. Teneriello, and A. Husain et al. OCEANS: a randomized, double-blind, placebo-controlled phase III trial of chemotherapy with or without bevacizumab in patients with platinum-sensitive recurrent epithelial ovarian, primary peritoneal, or fallopian tube cancer J Clin Oncol 30 2012 2039 2045
8. P. Harter, F. Hilpert, S. Mahner, S. Kommoss, F. Heitz, and A. du Bois Role of cytoreductive surgery in recurrent ovarian cancer Expert Rev Anticancer Ther 7 2009 917 922
9. R.E. Bristow, I. Puri, and D.S. Chi Cytoreductive surgery for recurrent ovarian cancer: a meta-analysis Gynecol Oncol 112 2009 265 274
10. P. Harter, A. du Bois, M. Hahmann, A. Hasenburg, A. Burges, and S. Loibl et al. Surgery in recurrent ovarian cancer: the Arbeitsgemeinschaft Gynaekologische Onkologie (AGO) DESKTOP OVAR trial Ann Surg Oncol 13 2006 1702 1710
11. M. Friedlander, E. Trimble, A. Tinker, D. Alberts, E. Avall-Lundquist, and M. Brady et al. Clinical trials in recurrent ovarian cancer Int J Gynecol Cancer 21 2011 771 775
12. P. Harter, J. Sehouli, A. Reuss, A. Hasenburg, G. Scambia, and D. Cibula et al. Prospective validation study of a predictive score for operability of recurrent ovarian cancer: the Multicenter Intergroup Study DESKTOP II. A project of the AGO Kommission OVAR, AGO Study Group, NOGGO, AGO-Austria, and MITO Int J Gynecol Cancer 21 2011 289 295
13. D. Dindo, N. Demartines, and P.A. Clavien Classification of surgical complications: a new proposal with evaluation in a cohort of 6336 patients and results of a survey Ann Surg 240 2004 205 213
14. J. Sehouli, R. Richter, E.l. Braicu, K.J. Bühling, M. Bahra, and M, P. Neuhaus et al. Role of secondary cytoreductive surgery in ovarian cancer relapse: who will benefit? A systematic analysis of 240 consecutive patients J Surg Oncol 102 6 Nov 1 2010 656 662
15. D.S. Chi, K. McCaughty, J.P. Diaz, J. Huh, S. Schwabenbauer, and A.J. Hummer et al. Guidelines and selection criteria for secondary cytoreductive surgery in patients with recurrent, platinum-sensitive epithelial ovarian carcinoma Cancer 106 9 May 1 2006 1933 1939
16. P. Harter, M. Hahmann, H.J. Lueck, O. Ortmann, M. Poelcher, and P. Wimberger et al. Surgery for recurrent ovarian cancer: role of peritoneal carcinomatosis: exploratory analysis of the DESKTOP I Trial about risk factors, surgical implications, and prognostic value of peritoneal carcinomatosis Ann Surg Oncol 16 5 2009 1324 1330